Nine publications this week:

• Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent β-thalassemia in the United States | link
• Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia | link
• Estimating the potential economic and health impact of integrated genomic surveillance in a hospital setting | link
• Direct cost savings associated with reduction in plasma metagenomic sequencing | link
• Assessing Willingness to Pay for Genetic Testing Among Adults: A Cross-Sectional Study Using Data from the Omnibus Survey 2022 | link
• Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer | link
• Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors | link
• The Impact of Adopting Whole-Genome Sequencing for Tuberculosis Diagnosis in China: A Cost-Effectiveness Analysis | link
• Diagnostics investments and disease burden | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.